ReviewRadiologie (Heidelberg, Germany)2026
[Enteral contrast agents-When, what and how?]
Review in Radiologie (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdministration of enteral contrast media (CM) in abdominal computed tomography (CT) is handled inconsistently across Germany.
objectiveTo present the current recommendations on administration of enteral contrast agents along the guiding questions of when, what and how and to translate them into radiological practice. MATERIAL AND
methodsSynthesis of indication-based recommendations, CM classes and their technical properties and the practical execution of both routes of administration, based on the recommendations of the German Röntgen Society (DRG), current guidelines, published evidence and institutional practice.
resultsPositive oral CMs are obsolete for most abdominal indications, including acute abdomen, ileus and trauma, and are contraindicated when gastrointestinal bleeding or ischemia is suspected. In cases of suspected perforation, routine oral contrast agents should be omitted and barium sulphate is contraindicated, whereas water-soluble iodinated agents remain an option when a leak has to be specifically demonstrated. Furthermore, enteral contrasting with neutral oral CM remains useful for upper gastrointestinal tumor staging and enterography (preferably magnetic resonance enterography).
conclusionAn indication-appropriate, guideline-based enteral contrast agent administration reduces unnecessary burden without compromising diagnostic accuracy and should be embedded in standardized workflows.
Indexed as
Identifiers
42860431What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.